Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
about
Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment optionsNew β-Lactamase Inhibitors in the ClinicInsights into Newer Antimicrobial Agents Against Gram-negative BacteriaProfile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infectionsWhat's new in multidrug-resistant pathogens in the ICU?Targeting Antibiotic ResistanceCost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections.Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactamCeftolozane/Tazobactam: a new option in the treatment of complicated gram-negative infections.Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.Polyphosphate Kinase Mediates Antibiotic Tolerance in Extraintestinal Pathogenic Escherichia coli PCN033Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model.Newer antibiotics for the treatment of peritoneal dialysis-related peritonitis.Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.Cephalosporins currently in early clinical trials for the treatment of bacterial infections.Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.Natural product and natural product derived drugs in clinical trials.Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials.Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria.Complicated Intra-Abdominal Infections: The Old Antimicrobials and the New Players.Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.Antimicrobial Resistance in the Intensive Care Unit: A Focus on Gram-Negative Bacterial Infections.Antibiotics: from prehistory to the present day.Ceftazidime-avibactam: novel antimicrobial combination for the treatment of complicated urinary tract infections.An update on emerging therapies for urinary tract infections.Examining the Clinical Effectiveness of Non-Carbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae.Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections.β-Lactams and β-Lactamase Inhibitors: An Overview.Emerging drugs for nosocomial pneumonia.Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications.Challenges and opportunities in the treatment of ventilator-associated pneumonia.PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal DiseaseKisameet Clay Isolated from the Central Coast of British Columbia, Canada, Demonstrates Broad-Spectrum Antimicrobial Activity.Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.Pharmacokinetics and Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers.Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art.Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy.What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
P2860
Q21146707-51270775-2632-4D7D-A4A6-A17976F1AA79Q26747150-D274C819-1559-4E7D-8BC2-D0A8FB21ED1DQ26751255-C99624E5-EF94-41AB-9F0A-0647F028577BQ27001490-58AA7329-3A6A-4483-83E8-CFD0BE2A1E1CQ28071346-02381969-9D23-430C-90E4-9088A1382F70Q28078130-5F0D869C-40D7-40B0-8272-FA2801244798Q33617939-71A964B0-F2A0-45E3-9235-D49A3D9DCC27Q33630591-5BB91F8D-5407-4598-B898-A59572F9A8C7Q34688710-F08C2CF8-BF8D-443B-ADC2-1D0BF0E23FC8Q36075893-0DADF064-A3D8-4847-8B18-F128247F725FQ36761826-E76B694F-CC24-4C4A-9575-0C66BA2D1193Q36913948-D6B4D94C-B158-41EB-9D53-4D706006B3C8Q37023118-15E7B50E-F889-44F7-B33B-BAA4E7C94BEFQ37119083-8B7C7E5A-8AAE-435C-BAB0-9524551DDA08Q37358630-4B933CDF-DDB6-4E86-8E62-33450EFFC4E1Q38222497-E0F7E3EA-5F04-4183-9C9E-CD79054A5301Q38241417-EB77A16F-9EA1-4059-B63E-4B243276D87FQ38247457-C851B267-D756-4017-9A7D-D09E431C6124Q38286351-2349814D-39DA-4E53-9C1D-D0B1AEC2CC1EQ38296151-03BC68FC-8ED5-491C-A7CA-1CB3D16C65F5Q38384662-A6B4B7C9-9486-4680-B434-9C392009B817Q38650049-8FFAACB6-41C8-4ACC-A13A-DB6C19483AFAQ38690748-A23063B0-7D9B-4147-B261-8E3CE8CFFBB1Q38697988-1E561938-ACCE-4368-AACE-6AA5F8CF6271Q38724754-281B56FC-A984-4F50-92CD-ABD5EBC391CCQ38740494-B46D0D60-62AA-4099-B43A-4BC0DF32C0B0Q38751454-8FF26D3C-48C3-41D8-BDA3-054B4F2D5D0EQ38792841-4C45D67A-7052-4064-A7A9-5CEF49E8C884Q38872130-8C1B016B-06AD-4F7C-A7E4-BB4FD008729FQ38872374-3688823C-1948-4F81-AA6F-640D9320B311Q38878167-0A41A880-804E-45D8-B304-324F15FB51DEQ38934400-229353ED-AA27-4E49-8C28-F19F9AB00716Q38988630-F190FE90-4A4B-4F05-AF47-01AE7BAC3008Q39066154-7FED2F53-C91B-4189-9830-2B62686A7DC8Q39597152-9AFC1CD4-C3CF-4955-935C-22543B6EDD4AQ39905753-4B493157-ECB7-4911-9734-454361483620Q40052714-D25C108D-5B5D-4F4F-84B7-31A420848C8DQ40095692-EB71A686-622C-4EBB-B47E-34BD0A03B845Q40187310-43C761E4-8A48-49A8-B013-BBF08E986803Q40550507-2D0FB2B8-16D2-4BBF-94C3-C42DE98A26BA
P2860
Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Ceftolozane/tazobactam: a nove ...... sistant gram-negative bacilli.
@ast
Ceftolozane/tazobactam: a nove ...... sistant gram-negative bacilli.
@en
Ceftolozane/tazobactam: a nove ...... sistant gram-negative bacilli.
@nl
type
label
Ceftolozane/tazobactam: a nove ...... sistant gram-negative bacilli.
@ast
Ceftolozane/tazobactam: a nove ...... sistant gram-negative bacilli.
@en
Ceftolozane/tazobactam: a nove ...... sistant gram-negative bacilli.
@nl
prefLabel
Ceftolozane/tazobactam: a nove ...... sistant gram-negative bacilli.
@ast
Ceftolozane/tazobactam: a nove ...... sistant gram-negative bacilli.
@en
Ceftolozane/tazobactam: a nove ...... sistant gram-negative bacilli.
@nl
P2093
P2860
P50
P1433
P1476
Ceftolozane/tazobactam: a nove ...... esistant gram-negative bacilli
@en
P2093
Alfred S Gin
Andrew Denisuik
Andrew Walkty
Daryl J Hoban
Ethan Rubinstein
Frank Schweizer
Heather Adam
James A Karlowsky
Joseph P Lynch
Phillip Chung
P2860
P2888
P356
10.1007/S40265-013-0168-2
P577
2014-01-01T00:00:00Z
P6179
1003597975